2025年生物追踪器数据监测医疗保健后ASCO报告_265页_4mb

2025 Biomedtracker Post-ASCO Report Summary

Core Content Overview

This report summarizes key clinical data and developments presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, focusing on oncology drugs and their potential in various indications. It includes insights on treatment efficacy, safety, and likelihood of approval (LOA) for multiple drugs across different cancers, as well as commentary from Biomedtracker analysts.

Main Sections Covered

• Acute Myelogenous Leukemia (AML)
• Bladder Cancer
• Brain Cancer (Malignant Glioma; AA and Glioblastoma (GBM))
• Chronic Myelogenous Leukemia (CML)
• Colorectal Cancer (CRC)
• Esophageal Cancer
• Gastric Cancer
• Head and Neck Cancer
• Multiple Myeloma (MM)
• Non-Small Cell Lung Cancer (NSCLC)
• Triple-Negative Breast Cancer (TNBC)
• Ovarian Cancer
• Prostate Cancer
• Renal Cell Cancer (RCC)
• Small Cell Lung Cancer (SCLC)
• Soft Tissue Sarcoma
• HER2+ Breast Cancer
• Hodgkin's Lymphoma
• HR+/HER2- Breast Cancer
• Melanoma
• Biomedtracker ASCO Events List

Key Findings and Highlights

Lisaftoclax for AML

• Event Date: May 22, 2025
• Trial: Phase I/II - APG2575AU101
• Lead Company: Ascentage Pharma Group Corporation
• Partner Companies: Innovent Biologics, MD Anderson Cancer Center
• LOA Change: +4% (now 15%)
• Results:
  • Overall response rate (ORR) in TN-MDS/CMML: 64%
  • Complete response (CR) rate in TN-MDS/CMML: 29%
  • Marrow CR rate in TN-MDS/CMML: 36%
  • ORR in R/R AML: 39% (28 days) and 50% (14 days)
  • CR rate in R/R AML: 28% (28 days) and 37.5% (14 days)
  • ORR in venetoclax-refractory HR-MDS: 50%
• Safety:
  • Combination well tolerated; no DLTs observed
  • Common grade 3/4 adverse events: neutropenia (40%), febrile neutropenia (31%), thrombocytopenia (22%)
  • No 60-day mortality reported
• Conclusion: Lisaftoclax in combination with azacitidine shows efficacy and safety, with promising results in patients with HR-MDS or AML. LOA was increased by 4% due to these findings.

Ziftomenib for AML

• Event Date: May 22, 2025
• Trial: Phase I/II - KO-MEN-001
• Lead Company: Kura Oncology, Inc.
• Partner Companies: Kyowa Kirin
• LOA Change: No change (92%)
• Results:
  • Phase II primary endpoint met (p=0.0058)
  • CR/CRh rate: 25% (all pts), 23% (Phase II pts)
  • ORR: 35%
  • MRD negativity: 67% among CR/CRh responders
• Safety:
  • 3% discontinuation rate due to TRAEs
  • 40% of pts had grade 3+ TRAEs, including differentiation syndrome (13%)
• Conclusion: Ziftomenib demonstrates deep and durable responses in R/R NPM1-m AML, with a favorable safety profile. It is a second menin inhibitor in development for AML.

Inqovi for AML

• Event Date: May 22, 2025
• Trial: Phase I/II - ASTX727-07
• Lead Company: Otsuka Holdings Co., Ltd.
• Partner Companies: Eisai
• LOA Change: +5% (now 49%)
• Results:
  • CR rate: 46.5%
  • CR with incomplete hematologic recovery: 63.4%
  • Median time to CR: 2.4 months
  • Median OS: 15.5 months
• Safety:
  • 98% of patients reported grade 3 or lower adverse events
  • Common events: febrile neutropenia (49.5%), anemia (38.6%), neutropenia (35.6%)
  • 30-day and 60-day mortality: 3% and 9%, respectively
• Conclusion: Inqovi, an all-oral regimen of DEC-C plus venetoclax, shows comparable safety and efficacy to parenteral AZA plus venetoclax in newly diagnosed AML ineligible for intensive induction chemotherapy.

Summary of Other Drugs

• Padcev, Opdivo, Yervoy, Trodelvy, Keytruda, Bavencio, Tookad, Sasanlimab, INB-200, Scemblix, Azacitidine for CMML, Tecentriq, JMT101, Stivarga, Opdivo, Braftovi, Vectibix, Olomorasib, KITE-363, VLS-101, Opdivo for Esophageal Cancer, Disitamab Vedotin, Imfinzi, Satri-cel, Enhertu, Opdivo for Gastric Cancer, APL-502, Orpathys, Krazati, Datroway, Zipalertinib, Relacorilant, Jemperli, IMNN-001, CAN-2409, ALLO-316, Casdatifan, Tecentriq for SCLC, Zepzelca, Imdelltra, Trodelvy for TNBC, Sacituzumab Tirumotecan, and others were also reviewed for their clinical performance and market potential at ASCO 2025.

Key Trends and Insights

• The report highlights the growing importance of targeted therapies and combination treatments in oncology.
• Drugs like lisaftoclax and ziftomenib are showing promising results in relapsed/refractory settings, particularly in AML.
• Inqovi’s all-oral regimen is a significant development for patients ineligible for intensive induction chemotherapy.
• The data suggest a need for new therapies to address resistance to existing treatments such as venetoclax.
• Safety profiles remain a critical factor in drug approval and market acceptance.

Conclusion

The 2025 ASCO meeting provided valuable insights into the efficacy and safety of various oncology drugs. The report emphasizes the importance of clinical data in shaping the future of cancer treatment and highlights the potential of new therapies to address unmet medical needs in relapsed/refractory and treatment-ineligible patient populations. Biomedtracker continues to monitor these developments closely and provides ongoing updates on likelihood of approval and commercial potential.